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Harbor- UCLA Medical Center, Torrance, CA, 5 Albany Medical Center, Albany, NY, 6 Cleveland Clinic Foundation, Cleveland, OH, 7 Inova Fairfax Hospital, Fairfax, VA, 8 Hospital of the University of Pennsylvania, Philadelphia, PA Background: Improvements in technique and devices promise improved outcomes following endovascular repair of aneurysms of the descending thoracic aortic. This mid-term report provides an update to the VALOR II trial results. Methods: VALOR II is a prospective, multicenter, observational study of endovascular treatment with the Valiant thoracic stent graft (Medtronic Endovascular Therapies, Santa Rosa, Calif) in patients with descending thoracic aortic aneurysms (TAA) of degenerative etiology. Results: VALOR II enrolled 160 patients between December 2006 to September 2009 and 1-year results have been previously reported. In this update, follow-up was available on 72% of patients through 3 years. One additional aneurysm-related death occurred after 1 year. One conversion to surgery was performed at 3 years in a patient who had continued aneurysm expansion in the absence of any observable endoleak. Seven secondary stent graft procedures were performed in 6 patients; 1 in the first 30 days, 3 after 1 year and 3 after 2 years. Freedom from secondary stent graft procedures was 94.9% at 3 years (95% CI: 88.8%-97.7%), which compared favorably with the earlier VALOR trial (85.1% at 3 years; 95% CI: 78.5%-89.8%), a study of the Talent thoracic stent graft with similar objectives and inclusion criteria. There was no type I or III endoleak reported at 2 or 3 years. Results: Mean length of ICU was halved with REVAR VS OR (PϽ0.008). Blood product requirements were 60% less in REVAR (PϽ0.0001). The Risk of ARDS and cardiac events were doubled if OR were performed .However there were no statistical significance in acute renal injury. Mean length of hospital stay was 7ϩ/Ϫ3 days for REVAR , and 12ϩ/Ϫ6 for OR (PϽ0.042).Thirty day mortality was 16% for REVAR vs 32% for OR ( PϽ0.001). Total Emergency mortality rate decreased from 64% to 28.2%. we attributed the Low Mortality Rate of 16%for REVAR Vs 32%in OR was due to introduction of an REVAR Programme which constitutes screening for prevention with early intervention and REVAR for rupture which has an absolute perioperative mortality reduction of 49% over OR. 5 years Survival of Patients with RAAA were 75% REVAR vs. 60% OR (pϭ0.0205). During 20th century 95% of all AAA were done surgically. However during 21st century 80% of AAA is done endovascularly. Mean Annual number of OR dropped (PϽ0.845) however Mean Annual number of EVARs had rocketed (PϽ0.006) . Overall number of AAA repairs has increased by 65% over twelve year's period but the absolute number of RAAA had declined by 24%. Conclusions: Para-Millennium and Contemporary Trends in AAA Management had shown Increased in Elective EVAR which increased the mortality advantage in favour of REVAR and it should be the Gold standard for RAAA.
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Background: The risk of clinical apparent, periprocedural stroke after thoracic endovascular aortic repair (TEVAR) ranges between 2 and 6% and has been associated with increased postoperative mortality. Stroke after TEVAR is thought to be related to multiple emboli, which are dislodged during manipulation of guidewires, catheters and large-bore delivery devices in the diseased aortic arch. Such emboli may also account for clinically silent cerebral ischemia. However, the rate of silent cerebral ischemia in the setting of TEVAR is yet unknown, but may be even higher than the rate of clinical apparent neurological events. Methods: Twenty patients (12 male, 8 female) who underwent TEVAR were included into this descriptive study; exclusion criteria were a history of stroke, carotid artery disease, renal failure and contraindications for magnetic resonance imaging (MRI). Periprocedural apparent and silent cerebral ischemia was assessed by neurological testing and serial cerebral diffusion-weighted MRI (DW-MRI) at baseline and within the first 10 days (mean: 4.9 days) post procedure. Results: TEVAR was successful in all patients without immediate clinically apparent neurological deficits. Post-interventional cerebral DW-MRI detected a total of 33 new foci of restricted diffusion in 13 of the 20 patients (65%). Lesions were usually multiple (1-6 lesions per patient) and ranged in size between 15 mm3 and 585 mm3. 17 lesions were found in the left middle cerebral artery and PICA territory, 10 lesions in the right middle cerebral artery and PICA territory. Overstenting of the left-subclavian artery was performed in 9 cases, but was not associated with lateralization of lesions. There were no additional apparent neurological events during the in-hospital period. Conclusions: TEVAR resulted in a high incidence of new foci of restricted diffusion on cerebral DW-MRI in a pattern suggestive for periprocedural embolization. Although even multiple lesions per patients were found, these lesions were not associated with apparent neurological deficits during the in-hospital period. Further developments in TEVAR should be directed towards reducing the risk of periprocedural cerebral embolization. Background: In the era of drug eluting stent, progression of non-culprit coronary lesion emerged as a new therapeutic target of coronary artery disease. We aimed to clarify the prognostic factors for the progression of non-culprit coronary lesion after percutaneous coronary intervention (PCI). Methods: We retrospectively examined 401 patients who underwent PCI during February 2010 to January 2011 in our institute. Among them, 275 patients were performed follow-up coronary angiography (CAG) 6-12 months after PCI. Patients with target lesion revascularization (nϭ39) were excluded. Finally, total of 236 patients were included in this study. Progression of non-culprit lesion was defined as clinically driven PCI because of the development of coronary lesion which was not significant at initial PCI but significant at follow-up CAG, and was associated with ischemic symptom and/or abnormal results of functional study. Results: Thirty three patients (14%) underwent additional clinically driven PCI to treat non-culprit coronary lesions. There was no difference in background clinical characteristics between patient with or without progression of non-culprit lesion PCI. Prevalence of chronic kidney disease (CKD) (61% vs. 31%, pϭ0.001) and multi-vessel disease (MVD) (55% vs. 35%, pϭ0.027) were significantly higher and statin use (61% vs. 72%, pϭ0.187) was tended to be lower in patients with non-culprit lesion PCI than those without. Brachial-ankle pulse wave velocity (baPWV) was significantly higher in patients with non-culprit lesion PCI than those without (1838Ϯ371 vs. 1589Ϯ313cm/s, pϽ0.001). High density lipoprotein cholesterol level at follow-up CAG was tended to be lower in patients with non-culprit lesion PCI than those without (54Ϯ15 vs. 58Ϯ16mg/dL, pϭ0.147). Multivariate analysis showed that higher baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants for progression of non-culprit coronary lesion. Conclusions: In conclusion, higher baPWV, CKD, MVD, and lower HDL at follow-up CAG were independent determinants of non-culprit coronary lesion PCI, suggesting important prognostic role of arterial stiffness and impaired renal function in the progression of non-culprit coronary artery lesion. Background: Recent insurance-based observational data indicate that the ratio of contrast volume (CV) use to calculated creatinine clearance predicts acute kidney injury (AKI). Whether these findings will be observed in other populations, is uncertain. Methods: 11,986 CATH and PCI procedures were performed at a single center (Wake Forest Baptist Medical Center) between January 2007 and December 2011 and were evaluated for AKI post-procedure. A contrast minimization strategy including automated contrast injection was used in all patients. Procedures with missing pre-or post-creatinine or renal failure with dialysis were excluded (nϭ4,117). Glomerular filtration rate was estimated (eGFR). Results: High risk baseline characteristics were significantly more prevalent with AKI (nϭ430) compared to no AKI (nϭ7,439), including CHF, diabetes, prior renal failure, acute MI, and elevated baseline creatinine. Per institutional standard of practice CV use was 20 mL lower per procedure for those with AKI (pϽ0.001), but CV/eGFR was 30% higher for those with AKI (pϽ0.001). After multivariable adjustment, CV/eGFR remained a significant independent predictor of AKI, with CV/eGFR Ն3.0 having 2.18 (1.59-3.00) increased odds of AKI vs. CV/eGFR Ͻ3.0 (see Figure) .
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Conclusions:
In this prospective observational registry CV/eGFR was independently predictive of AKI, with a ratio Ն3.0 associated with two-fold greater risk of AKI. These data provide strong support for the use of this metric as a risk-reduction method for AKI TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM www.jacc.tctabstracts2012.com
